Peptide

TB-500

Also known as

TB500 · TB-500 acetate · Thymosin Beta-4 fragment · Ac-LKKTETQ (analytical ID of many TB-500 products) · Tβ4 fragment (community shorthand) · LKKTETQ / Tβ4 (17–23) actin-binding region · TB-4 frag (often misused label)

Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.

What it is

Identity	A research peptide discussed for tendon problems, stiffness and soft-tissue recovery. The FDA-reviewed identity is the seven-amino-acid fragment Ac-LKKTETQ of thymosin beta-4.
Naming and routes	Forums also call full-length Tβ4 and other fragments TB-500. Injection reports dominate, under the skin (SubQ) or into muscle (IM); the shared name does not make products equivalent.

Notes

TB-500 is a research peptide discussed for stubborn tendon problems, stiffness and soft-tissue recovery. It is often paired with BPC-157 as the Wolverine stack. Reports range from easier movement to no benefit or troublesome fatigue, and products called TB-500 do not always contain the same peptide.

A fragment, with a naming problem. The FDA-reviewed identity is Ac-LKKTETQ, seven amino acids from the 43-amino-acid thymosin beta-4 protein. Forums also call full-length Tβ4 and other fragments TB-500; their evidence is not interchangeable. FDA July 2026 briefing: TB-500-related bulk drug substances (Official context · Accessed 2026-09-30) · Is the half life of TB4 different than the half life of TB500? (Secondhand community claim · Accessed 2026-09-30)

Injection accounts dominate the practical record. Subcutaneous means under the skin; intramuscular means into muscle. Original discussions include both, mostly research vials and combination products. Capsules and nasal sprays also appear, but skepticism about them does not measure absorption or prove that they cannot work.

Source context — FDA July 2026 briefing: TB-500-related bulk drug substances: Pre-meeting regulatory evidence review, not committee outcome, final compounding rule, human dosing study or universal proof of harm; horse concentrations are not half-life measurements.

Source context — Is the half life of TB4 different than the half life of TB500?: Forum repetition of clinic marketing and a different molecule's study; underlying clinic/article bodies not re-inspected. Numerical inconsistency belongs to the post, not a validated range. Date from indexed dated body.

What people notice

Movement and stiffness	Favorable reports describe quieter joints, easier movement or less pain during recovery. A shoulder log improved gradually while upper-body training was reduced.
Little or no benefit	One elbow account improved for about ten days, then saw little continuing benefit. Another reported no elbow improvement after a month at 2.5 mg three times weekly.
Symptoms versus repair	Less pain or easier knee movement does not establish healed tissue, particularly in blends or alongside rehabilitation.

Notes

Less stiffness and easier everyday movement. Users seek fewer painful movements, better range of motion and a return to training after strains or overuse. Favorable accounts describe quieter joints rather than a stimulant buzz or an instant pain switch.

Days to weeks in favorable reports. A TB-500-only shoulder log recorded gradual relief during its first two weeks, alongside reduced training. TB500 Log - Will it heal? (Personal report · Accessed 2026-09-30)

There may be no useful onset at all. An ExcelMale author felt early improvement for about ten days, then little continuing benefit for the elbow/thumb. Original notes use weeks 3–4 as a reassessment point and 4–6 weeks without change as a reason to reconsider injury, training load and rehabilitation. BPC157/TB500 Not helping (Personal report · Accessed 2026-09-30)

Nonresponse need not mean a counterfeit vial. An Eroids user reported no elbow improvement after a month at 2.5 mg three times weekly. They questioned both product quality and effectiveness. TB 500 your experience!!! (Community discussion · Accessed 2026-09-30)

Feeling better does not show repaired tissue. A GLOW user reported easier knee movement while planning repeat imaging of a meniscus tear. Combination accounts cannot identify which ingredient changed symptoms. My experience with TB500/BPC157 (Community discussion · Accessed 2026-09-30)

Bloodwork does not confirm tissue repair. Preserved discussions mention hs-CRP, ESR and CMP, rather than a routine TB-500 test; occasional iron talk is thin. Those tests do not identify the vial contents or show that a tendon healed. Less pain alone does not settle the diagnosis.

Source context — TB500 Log - Will it heal?: Older self-report, no confirmed sequence or product testing, rest/load confounding; claimed 'hypo' and allergic reaction are author interpretations without measurements. Not representative.

Source context — BPC157/TB500 Not helping: Reported 0.75 mg/day has unclear per-component meaning, so no precise dose was imported. New injury and combined products confound attribution. Sponsored forum context; no causal cyst claim used.

Source context — TB 500 your experience!!!: Old bodybuilding forum intertwined with seller reviews and other drugs; TB-4 vs fragment identity uncertain. No purchase details included; no prevalence or efficacy inference.

Source context — My experience with TB500/BPC157: Anonymous unverified combination reports; later relative timestamps are not exact dates. Thread includes supplier talk, which is excluded. Replies do not demonstrate causation, product identity or prevalence.

Doses people talk about

Recurring injection pattern	2–2.5 mg per injection twice weekly totals 4–5 mg/week. One SubQ account used 2.5 mg twice weekly for two weeks, then weekly for four; older load charts instead describe 4–6 weeks.
Higher schedules	Separate charts include 2–5 mg per shot, 5–10 mg/week, 5 mg twice weekly or 2–2.5 mg every other day. These are overlapping claims rather than equivalent schedules.
Daily Wolverine account	One author reports 500 mcg, or 0.5 mg, each of TB-500 and BPC-157 per day, five days/week, SubQ. That is each ingredient's amount, not a 500-mcg combined total.
Maintenance charts	2–2.5 mg weekly, broader 2–5 mg/week claims, 2 mg every two weeks and 2–6 mg/month all appear. No chart establishes a validated maintenance amount.

Notes

2–2.5 mg per injection, twice weekly, is one recurring pattern. That totals 4–5 mg/week. An opened SubQ account used 2.5 mg twice weekly for two weeks, then weekly for four. The original chart record describes 4–6-week loading; those are different course structures. Scary Experience with TB-500 (NEWBIE) (Community discussion · Accessed 2026-09-30)

Higher schedules also appear. Original charts include 2–5 mg per shot, 5–10 mg/week, 5 mg twice weekly, and 2–2.5 mg every other day. These overlap but are not equivalent schedules.

Daily combination use is another pattern. One Wolverine author reported 500 mcg (0.5 mg) each of TB-500 and BPC-157 per day, five days/week, SubQ. My experience with TB500/BPC157 (Community discussion · Accessed 2026-09-30)

Maintenance and weight-based charts disagree. Preserved charts describe 2–2.5 mg weekly (broader summaries say 2–5 mg/week), 2 mg every two weeks, or 2–6 mg/month. Clinic-style figures use 30–60 mcg/kg per injection twice weekly, then 30 mcg/kg weekly. These are unvalidated charts, not interchangeable human dose findings.

Source context — Scary Experience with TB-500 (NEWBIE): Unverified event with concurrent BPC, injection anxiety and inconsistent later frequency/unit statements. Commenters are not diagnosing clinicians. Preparation and sourcing instructions excluded.

Half-life, onset & duration

Felt onset	Favorable accounts describe gradual change over days to weeks. One Wolverine user noticed mild change in weeks 1–2 and much less pain in week three; some users never notice useful benefit.
Felt duration	One Wolverine account reports months of relief after a five-week course; another combined-use account relapsed about two weeks after stopping as activity rose and physiotherapy fell. Neither gives single-dose duration.
Half-life	No verified human fragment half-life emerges. Claims of 2–4 hours, 24–36 hours or 2–2.5 days conflict and often borrow full-Tβ4 evidence; the FDA review found no human TB-500 PK studies.

Notes

Week 3 was a turning point in one Wolverine account. That author described mild improvement in weeks 1–2, then much less pain. This is a course chronology, not single-dose onset. My experience with TB500/BPC157 (Community discussion · Accessed 2026-09-30)

Months of relief in one combination account. The Wolverine author later said knee pain stayed away for several months after a five-week course. My experience with TB500/BPC157 (Community discussion · Accessed 2026-09-30)

Roughly two weeks before aches returned in another account. The original combined-use record describes relapse after stopping as physiotherapy decreased and activity increased.

No dependable single-dose duration. One commenter claims 12–15 hours of downstream activity; another says days or weeks. These are mechanistic stories without measurements. Lasting symptom relief, continued tissue change and peptide remaining in blood are different questions. TB 500 Short Half Life? (Secondhand community claim · Accessed 2026-09-30)

2–4 hours is repeated without a TB-500 human measurement. One thread calls this a human half-life while equating TB-500 with thymosin beta-4. The preserved card also records 2–3-hour lore. Neither is established kinetics for the fragment; a dosing calendar cannot validate it. TB 500 Short Half Life? (Secondhand community claim · Accessed 2026-09-30)

24–36 hours and 2–2.5 days are competing claims. Another author quotes the first figure from a clinic page but describes the second in their own post. They are not equal. The roughly two-hour study claim discussed alongside them concerns full Tβ4, not proof for fragment TB-500. No verified human fragment half-life emerges from these discussions. Is the half life of TB4 different than the half life of TB500? (Secondhand community claim · Accessed 2026-09-30)

Animal detection is not human half-life. FDA found no human TB-500 pharmacokinetic studies. In horses given 10 mg SubQ, blood levels peaked at 1–2 hours and became unquantifiable at 6–10 hours. This is an animal detection window, not a half-life or a human relief timeline. FDA July 2026 briefing: TB-500-related bulk drug substances (Official context · Accessed 2026-09-30)

Source context — TB 500 Short Half Life?: Circulated uncited kinetic claims, not measurements; identity conflation. Date from indexed dated body corroborates opened discussion. Dosing advice in replies is not adopted.

Cycles people discuss

Load and maintenance charts	4–8-week blocks appear, sometimes with a 4–6-week load followed by lower-frequency use or stopping. Eight-week Wolverine charts sometimes split into four weeks loading and four maintenance.
Breaks and reruns	Multi-week breaks, stopping when symptoms settle, reruns after flares and months of maintenance all appear. No validated washout or safe indefinite-use calendar is established.

Notes

4–8-week blocks, sometimes with a 4–6-week load. Original charts describe higher-frequency loading followed by weekly or biweekly use, or stopping. Eight-week Wolverine charts sometimes divide into four weeks loading and four maintenance. Actual accounts do not all follow that template.

Breaks and extended use lack a settled rule. Multi-week breaks, stopping when symptoms settle, reruns after another flare and months of lower-frequency maintenance all remain in the record. There is no validated washout calendar or established safety for indefinite use. Training-day, rest-day and time-of-day preferences also differ.

Stacks

Wolverine	TB-500 plus BPC-157 is the recurring injury/recovery pair. Daily BPC with less frequent TB and daily combined use are different patterns.
GLOW and KLOW	GLOW adds GHK-Cu; one vial example is 50/10/10 mg GHK-Cu/BPC/TB. KLOW adds KPV. Ratios vary, and a blend's total or syringe marks do not give each ingredient's amount.
Other recovery layers	GH-axis compounds, physiotherapy, mobility work, sleep and deloads recur. These make the contribution of TB-500 difficult to separate.

Notes

Wolverine (core): TB-500 + BPC-157 — highest-volume dual injury/recovery stack name. [community]

Wolverine schedule pattern: BPC daily (or 2×/day) SubQ near complaint site + TB 2×/week load → 1×/week maintain, often different injection sites. [community]

A blend's total is not its TB-500 amount. Preserved commercial/community examples list GLOW as 50/10/10 mg GHK-Cu/BPC-157/TB-500 (5:1:1), KLOW as 50/10/10/10 mg with KPV, and Wolverine as 5 mg BPC plus 10 mg TB per vial. Ratios vary. Daily blend discussions around 0.3 mg TB differ from standalone multi-mg injections.

Milligrams, micrograms and syringe marks are different. 1 mg equals 1,000 mcg. BPC co-use is often recorded as 250–500 mcg/day, sometimes 200–500 mcg once or twice daily. Syringe units describe volume, not a universal peptide amount; copied unit charts and vial totals can mislead.

GLOW: TB-500 + BPC-157 + GHK-Cu — skin/collagen + recovery threads; common pre-mix ratio talk ~5:1:1 GHK:BPC:TB (e.g. 50/10/10 mg). Ratios vary. [community]

KLOW: GLOW ingredients + KPV — inflammation/gut-adjacent upgrade path in blend marketing. [community]

Daily blends and separate schedules answer different practical questions. Some people want fewer injections or one mixed product; others want separate amounts and clearer attribution. Adding GHK-Cu, KPV or GH-axis compounds makes that attribution harder. Mobility work, deliberate deloads, physiotherapy and sleep remain part of recovery accounts.

GH-axis adjacency: Sometimes layered with CJC-1295/Ipamorelin, sermorelin, or MK-677 for “recovery lifestyle” — heavily confounded. [community]

Non-drug stack: Physical therapy, mobility work, sleep, and deliberate deloads are repeatedly credited alongside peptide blocks. [community]

Watch for

Fatigue and local symptoms	Reports include lethargy, flu-like feelings, headache, dizziness, nausea, soreness and itching. One combined BPC/TB author reported flu-like symptoms again on restarting.
Fainting account	A novice reported dizziness, nausea and loss of consciousness after 2.5 mg SubQ. Replies proposed needle-related fainting, but the thread cannot diagnose the event or establish that retrying is safe.
Identity, approval and sport	FDA flags impurity, aggregation and immune-response concerns. Compounding discussion is not drug approval; the saved 2026 WADA list prohibits TB-500. Cancer/angiogenesis questions remain unresolved.

Notes

Fatigue and feeling unwell are real reports. One BPC/TB author described lethargy and flu-like symptoms twice, after stopping and restarting. The original record also includes headache, dizziness, nausea and local soreness/itching; less prominent reports mention warmth, fluid retention and sleep or mood changes. Causes and frequency remain uncertain. Fatigue from Peptides? BPC157/TB500 (Personal report · Accessed 2026-09-30)

A fainting report is not a diagnosed harmless reaction. A novice reported dizziness, nausea and loss of consciousness after a 2.5 mg SubQ shot. Replies suggested needle-related fainting, and a retry reportedly went well. The thread cannot diagnose the event or establish that repeating an injection is safe. Scary Experience with TB-500 (NEWBIE) (Community discussion · Accessed 2026-09-30)

Product identity and immune reactions matter. FDA highlights impurity, aggregation and immune-response concerns. Community purity claims do not establish safety; cancer/angiogenesis worries remain unresolved. FDA July 2026 briefing: TB-500-related bulk drug substances (Official context · Accessed 2026-09-30)

Approval and tested sport are separate questions. The reviewed TB-500 substances are not components of an FDA-approved drug; compounding committee discussion is not drug approval. WADA's 2026 list expressly prohibits thymosin beta-4 derivatives including TB-500. The original record also raises pregnancy/breastfeeding uncertainty. FDA July 2026 briefing: TB-500-related bulk drug substances (Official context · Accessed 2026-09-30) · WADA 2026 Prohibited List (Official context · Accessed 2026-09-30)

Source context — Fatigue from Peptides? BPC157/TB500: No dose or confirmed vial identity; combination use and possible illness; temporal association is not causation. Exact post date not established from relative UI date.

Source context — WADA 2026 Prohibited List: Anti-doping status, not general legal classification, clinical safety or kinetics; current 2026 list only.

Full notes

What TB-500 means in these discussions

A fragment, with a naming problem. The FDA-reviewed identity is Ac-LKKTETQ, seven amino acids from the 43-amino-acid thymosin beta-4 protein. Forums also call full-length Tβ4 and other fragments TB-500; their evidence is not interchangeable. Official context Reddit · r/Peptides
The systemic half of Wolverine. Community shorthand casts BPC-157 as near-injury repair and TB-500 as wider mobility support. That is a mental model, not a proven comparison. Both distant and near-injury injection accounts appear; neither location establishes better healing. Community
Injection accounts dominate the practical record. Subcutaneous means under the skin; intramuscular means into muscle. Original discussions include both, mostly research vials and combination products. Capsules and nasal sprays also appear, but skepticism about them does not measure absorption or prove that they cannot work. Community

What people hope to get—and how it may feel

Less stiffness and easier everyday movement. Users seek fewer painful movements, better range of motion and a return to training after strains or overuse. Favorable accounts describe quieter joints rather than a stimulant buzz or an instant pain switch. Community
Feeling better does not show repaired tissue. A GLOW user reported easier knee movement while planning repeat imaging of a meniscus tear. Combination accounts cannot identify which ingredient changed symptoms. Reddit · r/Biohackers

Doses people report

These are descriptions of community use and circulated charts, not a dosing recommendation.

2–2.5 mg per injection, twice weekly, is one recurring pattern. That totals 4–5 mg/week. An opened SubQ account used 2.5 mg twice weekly for two weeks, then weekly for four. The original chart record describes 4–6-week loading; those are different course structures. Reddit · r/PeptideDiscussion Community
Higher schedules also appear. Original charts include 2–5 mg per shot, 5–10 mg/week, 5 mg twice weekly, and 2–2.5 mg every other day. These overlap but are not equivalent schedules. Community
Daily combination use is another pattern. One Wolverine author reported 500 mcg (0.5 mg) each of TB-500 and BPC-157 per day, five days/week, SubQ. Reddit · r/Biohackers
Maintenance and weight-based charts disagree. Preserved charts describe 2–2.5 mg weekly (broader summaries say 2–5 mg/week), 2 mg every two weeks, or 2–6 mg/month. Clinic-style figures use 30–60 mcg/kg per injection twice weekly, then 30 mcg/kg weekly. These are unvalidated charts, not interchangeable human dose findings. Community
A blend's total is not its TB-500 amount. Preserved commercial/community examples list GLOW as 50/10/10 mg GHK-Cu/BPC-157/TB-500 (5:1:1), KLOW as 50/10/10/10 mg with KPV, and Wolverine as 5 mg BPC plus 10 mg TB per vial. Ratios vary. Daily blend discussions around 0.3 mg TB differ from standalone multi-mg injections. Community Community
Milligrams, micrograms and syringe marks are different. 1 mg equals 1,000 mcg. BPC co-use is often recorded as 250–500 mcg/day, sometimes 200–500 mcg once or twice daily. Syringe units describe volume, not a universal peptide amount; copied unit charts and vial totals can mislead. Community

Half-life: conflicting community numbers

2–4 hours is repeated without a TB-500 human measurement. One thread calls this a human half-life while equating TB-500 with thymosin beta-4. The preserved card also records 2–3-hour lore. Neither is established kinetics for the fragment; a dosing calendar cannot validate it. Reddit · r/PeptideDiscussion Community
24–36 hours and 2–2.5 days are competing claims. Another author quotes the first figure from a clinic page but describes the second in their own post. They are not equal. The roughly two-hour study claim discussed alongside them concerns full Tβ4, not proof for fragment TB-500. No verified human fragment half-life emerges from these discussions. Reddit · r/Peptides

Onset: when users notice a change

Days to weeks in favorable reports. A TB-500-only shoulder log recorded gradual relief during its first two weeks, alongside reduced training. Personal report
Week 3 was a turning point in one Wolverine account. That author described mild improvement in weeks 1–2, then much less pain. This is a course chronology, not single-dose onset. Reddit · r/Biohackers
There may be no useful onset at all. An ExcelMale author felt early improvement for about ten days, then little continuing benefit for the elbow/thumb. Original notes use weeks 3–4 as a reassessment point and 4–6 weeks without change as a reason to reconsider injury, training load and rehabilitation. Personal report Community

Duration: relief after stopping is variable

Months of relief in one combination account. The Wolverine author later said knee pain stayed away for several months after a five-week course. Reddit · r/Biohackers
Roughly two weeks before aches returned in another account. The original combined-use record describes relapse after stopping as physiotherapy decreased and activity increased. Community
No dependable single-dose duration. One commenter claims 12–15 hours of downstream activity; another says days or weeks. These are mechanistic stories without measurements. Lasting symptom relief, continued tissue change and peptide remaining in blood are different questions. Reddit · r/PeptideDiscussion

Cycles and maintenance discussions

4–8-week blocks, sometimes with a 4–6-week load. Original charts describe higher-frequency loading followed by weekly or biweekly use, or stopping. Eight-week Wolverine charts sometimes divide into four weeks loading and four maintenance. Actual accounts do not all follow that template. Community
Breaks and extended use lack a settled rule. Multi-week breaks, stopping when symptoms settle, reruns after another flare and months of lower-frequency maintenance all remain in the record. There is no validated washout calendar or established safety for indefinite use. Training-day, rest-day and time-of-day preferences also differ. Community Community

What could change the decision

Fatigue and feeling unwell are real reports. One BPC/TB author described lethargy and flu-like symptoms twice, after stopping and restarting. The original record also includes headache, dizziness, nausea and local soreness/itching; less prominent reports mention warmth, fluid retention and sleep or mood changes. Causes and frequency remain uncertain. Personal report Community
A fainting report is not a diagnosed harmless reaction. A novice reported dizziness, nausea and loss of consciousness after a 2.5 mg SubQ shot. Replies suggested needle-related fainting, and a retry reportedly went well. The thread cannot diagnose the event or establish that repeating an injection is safe. Reddit · r/PeptideDiscussion
Product identity and immune reactions matter. FDA highlights impurity, aggregation and immune-response concerns. Community purity claims do not establish safety; cancer/angiogenesis worries remain unresolved. Official context Community
Approval and tested sport are separate questions. The reviewed TB-500 substances are not components of an FDA-approved drug; compounding committee discussion is not drug approval. WADA's 2026 list expressly prohibits thymosin beta-4 derivatives including TB-500. The original record also raises pregnancy/breastfeeding uncertainty. Official context Official context Community

What the recovery stories leave unresolved

Nonresponse need not mean a counterfeit vial. An Eroids user reported no elbow improvement after a month at 2.5 mg three times weekly. They questioned both product quality and effectiveness. Eroids
Maintenance may not keep pain away. Another account described relapse at 2 mg every two weeks, but called it TB-4 and also used growth hormone: identity and attribution uncertain. Eroids
Early fatigue can have other explanations. A preserved commenter described first-week headache and fatigue resolving after week two, then disclosed low magnesium/vitamin D and added supplements. That timeline cannot isolate TB-500. Community
Daily blends and separate schedules answer different practical questions. Some people want fewer injections or one mixed product; others want separate amounts and clearer attribution. Adding GHK-Cu, KPV or GH-axis compounds makes that attribution harder. Mobility work, deliberate deloads, physiotherapy and sleep remain part of recovery accounts. Community
Bloodwork does not confirm tissue repair. Preserved discussions mention hs-CRP, ESR and CMP, rather than a routine TB-500 test; occasional iron talk is thin. Those tests do not identify the vial contents or show that a tendon healed. Less pain alone does not settle the diagnosis. Community

Supporting context, separate from community timing

Animal detection is not human half-life. FDA found no human TB-500 pharmacokinetic studies. In horses given 10 mg SubQ, blood levels peaked at 1–2 hours and became unquantifiable at 6–10 hours. This is an animal detection window, not a half-life or a human relief timeline. Official context